We are live on ! Find out more
BC

Birchview Capital Portfolio holdings

AUM $176M
1-Year Est. Return 95.04%
This Fund
S&P 500
This Quarter Est. Return
+4.62%
1 Year Est. Return
+95.04%
3 Year Est. Return
+233.14%
5 Year Est. Return
+280.2%
10 Year Est. Return
+1,023.63%
AUM
$115M
AUM Growth
-$7.74M
Cap. Flow
-$373K
Cap. Flow %
-0.32%
Top 10 Hldgs %
66.12%
Holding
72
New
4
Increased
20
Reduced
11
Closed
4

Top Buys

Rank Stock Value
1
QURE icon
uniQure
QURE
+$963K
2
SLDB icon
Solid Biosciences
SLDB
+$551K
3
KIDS icon
OrthoPediatrics
KIDS
+$494K
4
XENE icon
Xenon Pharmaceuticals
XENE
+$418K
5
PRTA icon
Prothena Corp
PRTA
+$402K

Top Sells

Rank Stock Value
1
ACAD icon
Acadia Pharmaceuticals
ACAD
+$1.36M
2
UTHR icon
United Therapeutics
UTHR
+$857K
3
MASI
Masimo
MASI
+$694K
4
AXGN icon
Axogen
AXGN
+$650K
5
CORT icon
Corcept Therapeutics
CORT
+$487K

Sector Composition

Rank Sector Weight
1 Healthcare 96.33%
2 Energy 3.55%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XENE icon
26
Xenon Pharmaceuticals
XENE
$6.38B
$705K 0.61%
21,000
+11,000
+110% +$418K
AXSM icon
27
Axsome Therapeutics
AXSM
$11.4B
$700K 0.61%
6,000
+2,000
+50% +$228K
KNSA icon
28
Kiniksa Pharmaceuticals
KNSA
$4.81B
$666K 0.58%
30,006
+6
+0% +$123
HALO icon
29
Halozyme
HALO
$9.14B
$638K 0.55%
10,000
– –
RARE icon
30
Ultragenyx Pharmaceutical
RARE
$2.81B
$579K 0.5%
16,000
– –
NVCR icon
31
NovoCure
NVCR
$1.85B
$552K 0.48%
31,000
– –
SRRK icon
32
Scholar Rock
SRRK
$6.07B
$514K 0.45%
16,000
+8,000
+100% +$308K
KIDS icon
33
OrthoPediatrics
KIDS
$501M
$493K 0.43%
+20,000
New +$494K
SLDB icon
34
Solid Biosciences
SLDB
$832M
$476K 0.41%
+128,768
New +$551K
INBX icon
35
Inhibrx
INBX
$1.23B
$449K 0.39%
32,110
– –
TXG icon
36
10x Genomics
TXG
$5.49B
$437K 0.38%
50,000
– –
CYTK icon
37
Cytokinetics
CYTK
$10.7B
$402K 0.35%
10,000
– –
SWTX
38
DELISTED
SpringWorks Therapeutics
SWTX
$365K 0.32%
8,280
-1,720
-17% -$79.2K
LUNG icon
39
Pulmonx
LUNG
$57M
$343K 0.3%
51,000
– –
CADL icon
40
Candel Therapeutics
CADL
$701M
$339K 0.29%
60,000
– –
ATEC icon
41
Alphatec Holdings
ATEC
$1.27B
$335K 0.29%
33,000
-25,000
-43% -$268K
WVE icon
42
Wave Life Sciences
WVE
$1.1B
$326K 0.28%
40,300
+300
+0.8% +$3.28K
MLTX icon
43
MoonLake Immunotherapeutics
MLTX
$1.59B
$313K 0.27%
8,000
+4,000
+100% +$172K
APLS
44
DELISTED
Apellis Pharmaceuticals
APLS
$306K 0.27%
14,000
– –
BCRX icon
45
BioCryst Pharmaceuticals
BCRX
$2.32B
$300K 0.26%
40,000
– –
APGE icon
46
Apogee Therapeutics
APGE
$10.1B
$299K 0.26%
+8,000
New +$309K
XNCR icon
47
Xencor
XNCR
$1.39B
$277K 0.24%
26,000
– –
OM icon
48
Outset Medical
OM
$75.3M
$272K 0.24%
24,584
– –
BPMC
49
DELISTED
Blueprint Medicines
BPMC
$239K 0.21%
2,700
– –
FOLD
50
DELISTED
Amicus Therapeutics
FOLD
$228K 0.2%
28,000
– –
1
2
3

Similar funds

RWA
Resolute Wealth Advisor Findlay, Ohio $176M AUM
BAM
Boyar Asset Management New York $176M AUM 20.04% 1-Year Est. Return
TIM
Tevis Investment Management Plano, Texas $176M AUM 18.14% 1-Year Est. Return
TFCM
Taylor Frigon Capital Management Scottsdale, Arizona $176M AUM 24.25% 1-Year Est. Return
FPW
Flywheel Private Wealth Los Altos, California $176M AUM 26.12% 1-Year Est. Return
LWM
Lifetime Wealth Management Rockwall, Texas $176M AUM
PFA
Providence Financial Advisors Overland Park, Kansas $175M AUM
DAM
Draper Asset Management Smithtown, New York $176M AUM 37.45% 1-Year Est. Return

Birchview Capital's Q1 2025 Portfolio in Review

As of Q1 2025, Birchview Capital held 72 positions worth $115M, down 6.3% from $123M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Birchview Capital's Q1 2025 filing shows 4 new, 20 increased, 11 reduced and 4 closed positions. Its largest new stake was Solid Biosciences: 128,768 shares worth $476K. The largest sale was Acadia Pharmaceuticals, an estimated $1.36M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier, followed by Energy.

  • Birchview Capital's largest Q1 2025 buy was Solid Biosciences: 128,768 shares worth $476K.
  • Birchview Capital added most to uniQure in Q1 2025, an estimated $963K increase.
  • Birchview Capital's biggest Q1 2025 reduction was Acadia Pharmaceuticals, cutting an estimated $1.36M.
  • Birchview Capital fully exited Sarepta Therapeutics in Q1 2025, selling an estimated $426K.
  • Birchview Capital's ten largest holdings make up 66% of its $115M portfolio in Q1 2025.
  • Birchview Capital opened 4 new positions and closed 4 in Q1 2025.
  • Birchview Capital's portfolio value fell 6.3% quarter-over-quarter to $115M.

Based on Birchview Capital's 13F filing for Q1 2025, filed 15 May 2025.